Preclinical studies with erlotinib (Tarceva)

Seminars in Oncology

Volumn 30, Issue 3 SUPPL. 7, 2003, Pages 15-24

  Akita, Robert W ^b   Sliwkowski, Mark X ^a  

^a GENENTECH INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; ERLOTINIB; GEMCITABINE; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; COLORECTAL CANCER; CONFERENCE PAPER; DRUG MECHANISM; DRUG RESISTANCE; DRUG SCREENING; ENZYME ACTIVITY; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; PANCREAS CANCER; PHOSPHORYLATION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH;

EID: 0037667417     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)70011-6     Document Type: Conference Paper

References (51)

1. Jones JT, Akita RW, Sliwkowski MX: Binding specificities and affinities of EGF domains for ErbB receptors. FEBS Lett 447:227-231, 1999
2. Yarden Y, Sliwkowski MX: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2:127-137, 2001
3. Salomon DS, Brandt R, Ciardiello F, et al: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232, 1995
4. Arteaga CL: The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19:32S-40S, 2001
5. Wells A: EGF receptor. Int J Biochem Cell Biol 31:637-643, 1999
6. Moyer JD, Barbacci EG, Iwata KK, et al: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57:4838-4848, 1997
7. Pollack VA, Savage DM, Baker DA, et al: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291:739-748, 1999
8. Desai B, Higgins B, Smith M: Antitumor activity of the EGFR/TK inhibitor Tarceva (erlotinib, OSI-774) tumor models. Eur J Cancer 38:63, 2002 (suppl 7) (abstr 203)
9. Ng SS, Tsao MS, Nicklee T, et al: Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther 1:777-783, 2002
10. Ekstrand AJ, Longo N, Hamid ML, et al: Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 9:2313-2320, 1994
11. Nishikawa R, Ji XD, Harmon RC, et al: A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 91:7727-7731, 1994
12. Moscatello DK, Montgomery RB, Sundareshan P, et al: Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 13:85-96, 1996
13. Prigent SA, Nagane M, Lin H, et al: Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem 271:25639-25645, 1996
14. Lal A, Glazer CA, Martinson HM, et al: Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 62:3335-3339, 2002
15. Damstrup L, Wandahl Pedersen M, Bastholm L, et al: Epidermal growth factor receptor mutation type III transfected into a small cell lung cancer cell line is predominantly localized at the cell surface and enhances the malignant phenotype. Int J Cancer 97:7-14, 2002
16. Iwata KK, Provoncha K, Gibson N: Inhibition of mutant EGFRvlll transformed cells by tyrosine kinase inhibitor OSI-774 (Tarceva). Proc Am Soc Clin Oncol 21:21a, 2002 (abstr 79)
17. Wong AJ, Ruppert JM, Bigner SH, et al: Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 89:2965-2969, 1992
18. Pérez-Soler R, Chachoua A, Huberman M, et al: A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced-EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20:310a, 2001 (abstr 1235)
19. Pérez-Soler R, Chachoua A, Huberman M., et al: Determinants of tumor response and survival in patients with relapsing NSCLC treated with Tarceva (erlotinib HCl; OSI-774). Final report of a phase II study. Presented at the American Society of Clinical Oncology and Molecular Therapy Symposium, San Diego, CA, November 8-10, 2002
20. Finkler N, Gordon A, Crozier M, et al: Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proc Am Soc Clin Oncol 20:208a, 2001 (abstr 831)
21. Senzer NN, Soulieres D, Siu L, et al: Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 20:2a, 2001 (abstr 6)
22. Hidalgo M: Phase I studies/combination therapy with Tarceva (erlotinib HCl;OSI-774) in head and neck cancer. Presented at the First Annual Opinion Leader Consortium on Novel and Targeted Therapies for Head and Neck Cancer, San Juan, Puerto Rico, February 5-9, 2003
23. Graus-Porta D, Beerli RR, Daly JM, et al: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16:1647-1655, 1997
24. Akita RW, Dugger D, Lewis Phillips G, et al: Effects of the EGFR inhibitor Tarceva on activated ErbB2. Proc Am Assoc Cancer Res 43:1003, 2002 (abstr 4973)
25. Kraus MH, Popescu NC, Amsbaugh SC, et al: Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 6:605-610, 1987
26. Normanno N, Campiglio M, De Luca A, et al: Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 13:65-72, 2002
27. Moulder SL, Yakes FM, Muthuswamy SK, et al: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61:8887-8895, 2001
28. Lenferink AE, Simpson JF, Shawver LK, et al: Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice. Proc Natl Acad Sci U S A 97:9609-9614, 2000
29. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241-250, 1999
30. De Miguel P, Royuela M, Bethencourt R, et al: Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates. Cytokine 11:722-727, 1999
31. Normanno N, Kim N, Wen D, et al: Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas. Breast Cancer Res Treat 35:293-297, 1995
32. Etessami A, Bourhis J: Cetuximab. Anti-EGFR monoclonal antibody. Drugs Fut 25:895-899, 2000
33. Chen X, Yeung TK, Wang Z: Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. Biochem Biophys Res Commun 277:757-763, 2000
34. Mita A, Farouzesh B, Hidalgo M: Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor receptor-tyrosine kinase (HER1/EGFR-TK) inhibitor erlotinib (OSI-774; Tarceva) in combination with docetaxel. Eur J Cancer 38:53, 2002 (suppl 7) (abstr 168)
35. Ratain MJ, George CM, Janisch L, et al: Phase I trial of erlotinib (OSI-774) in combination with gemcitabine (G) and cisplatin (P) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 21:76b, 2002 (abstr 2115)
36. Patnaik A, Goetz A, Hammond L, et al: Phase I, pharmacokinetic (PK) and biologic study of OSI-774 (Tarceva), a selective epidermal growth factor receptor (EGFR) tyrsoine kinase (TK) inhibitor in combination with paclitaxel and carboplatin in patients with advanced solid malignancies. Eur J Cancer 38:54, 2002 (suppl 7) (abstr 169)
37. Wu H, Kim J, Cao Q, et al: Combined modality therapy of NCI-H460 human lung cancer using epidermal growth factor receptor inhibition, OSI-774 and ionizing radiation in vitro and in vivo. Int J Radiat Oncol 54: 176, 2002 (suppl) (abstr 1031)
38. Harari PM, Huang SM: Epidermal growth factor receptor modulation of radiation response: preclinical and clinical development. Semin Radiat Oncol 12:21-26, 2002
39. Nicholson RI, Hutcheson IR, Harper ME, et al: Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Ann N Y Acad Sci 963:104-115, 2002
40. Wakeling AE, Nicholson RI, Gee JM: Prospects for combining hormonal and nonhormonal growth factor inhibition. Clin Cancer Res 7:4350s-4355s, 2001
41. Gee JM, Hutcheson IR, Knowlden JM, et al: The EGFR-selective yrosine kinase inhibitor ZD1839 (Iressa) is an effective inhibitor of tamoxifen-resistant breast cancer growth. Proc Am Soc Clin Oncol 20:71a, 2001 (abstr 282)
42. Kokai Y, Myers JN, Wada T, et al: Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58:287-292, 1989
43. Muller W, Arteaga CL, Muthuswamy SK, et al: Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Mol Cell Biol 16:5726-5736, 1996
44. Christensen JG, Schreck RE, Chan E, et al: High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin Cancer Res 7:4230-4238, 2001
45. Harris AL: Epidermal growth factor receptor in human breast cancer. Recent Results Cancer Res 113:70-77, 1989
46. Tateishi M, Ishida T, Kohdono S, et al: Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma. Surg Oncol 3:109-113, 1994
47. Agus DB, Akita RW, Fox WD, et al: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127-137, 2002
48. Totpal K, Lewis-Phillips GD, Balter I, et al: Augmentation of rhuMAb2C4 induced growth inhibition by Tarceva the EGFR tyrosine kinase inhibitor on human breast cancer cell line. Proc Am Assoc Cancer Res. 43:789, 2002 (abstr 3889)
49. Kerbel R, Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727-739, 2002
50. Ciardiello F, Caputo R, Bianco R, et al: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7: 1459-1465, 2001
51. Petit AM, Rak J, Hung MC, et al: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523-1530, 1997